Evotec SE stock (DE0005664809): Outlook after Nasdaq delisting and latest business update

After the surprise Nasdaq delisting and delayed 2023 annual report, Evotec SE remains a closely watched German biotech stock. How the latest financial update and strategic focus on partnerships shape the outlook for US-oriented investors.

Evotec SE has been in the spotlight over the past months after the company’s American Depositary Shares were delisted from Nasdaq following delays in publishing its 2023 annual report, while the primary listing in Frankfurt continues and the drug discovery specialist pushes ahead with new partnerships and pipeline projects, according to the company and exchange notices published in 2024 and early 2025 (Evotec newsroom as of 2025).

In its most recent available business update, Evotec reported continued revenue growth from its collaborative discovery and development platforms, highlighting multi-year alliances with large pharma partners and a growing base of biotech and academic clients, as outlined in company presentations and financial documents released in 2024 (Evotec investor information as of 2024).

As of: 08.06.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Evotec
• Sector/industry: Biotechnology / drug discovery and development services
• Headquarters/country: Hamburg, Germany
• Core markets: Global pharma and biotech research collaborations with strong exposure to Europe and the United States
• Key revenue drivers: Research collaborations, milestones and licensing income from partnered drug candidates
• Home exchange/listing venue: Frankfurt Stock Exchange (Xetra), ticker often quoted as EVT in Germany
• Trading currency: Euro (EUR) for the primary Frankfurt listing

Evotec SE: core business model

Evotec SE positions itself as a fully integrated drug discovery and development partner for pharmaceutical companies, biotech firms and academic institutions, focusing on early research through clinical development across multiple disease areas, according to its corporate profile and investor materials published in 2024 (Evotec company information as of 2024).

The company operates a so?called “co-owned pipeline” model, combining traditional fee-for-service research contracts with shared ownership of selected drug candidates, which can generate milestone payments and potential royalties if partnered assets progress successfully, as described in corporate presentations from 2024 (Evotec presentations as of 2024).

Evotec’s scientific platform spans discovery chemistry, biology, screening, preclinical development and certain clinical capabilities, allowing partners to outsource a broad spectrum of R&D tasks while accessing specialized technologies such as high-throughput screening, induced pluripotent stem cell platforms and data-driven drug design, according to the company’s technology overview and partner descriptions released in 2024 (Evotec platforms overview as of 2024).

Main revenue and product drivers for Evotec SE

Evotec generates most of its revenues from multi-year research and development collaborations with large pharmaceutical companies, which pay for access to Evotec’s discovery platforms, dedicated project teams and integrated R&D capabilities, as described in the company’s financial reporting and partner case studies released in 2024 (Evotec partnering overview as of 2024).

In addition to service-like revenues, Evotec’s business model includes milestone payments and potential royalty streams tied to the progress and commercial success of partnered drug candidates, meaning that later-stage pipeline achievements can create high-margin revenue events, according to detailed explanations in the firm’s investor presentations and annual reports published for 2023 and 2024 (Evotec reports and publications as of 2024).

The company focuses on several therapeutic areas, including neuroscience, metabolic diseases, oncology and infectious diseases, and it highlights that diversification across indications and partners can help manage the inherent risk of drug development, based on portfolio descriptions and pipeline overviews released in 2024 (Evotec pipeline overview as of 2024).

Conclusion

Evotec SE remains a notable European biotech player with a global partner network, even after the disruption caused by its past Nasdaq delisting and reporting delays, while its primary Frankfurt listing and ongoing collaborations continue to attract attention from internationally oriented investors, according to company disclosures and exchange notices published since 2024 (Börse Frankfurt company profile as of 2025). For US-focused investors, the stock offers exposure to outsourced drug discovery and co-owned pipelines without being a US domestic listing, which may influence trading access, liquidity and FX considerations compared with US-based biotech peers, as indicated by market data and listing information from European exchanges in 2025 (Deutsche Börse factsheet as of 2025). The balance between recurring collaboration revenues and the long-term uncertainty of drug development outcomes remains central to how the market could value Evotec’s shares over time.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.